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Abstract
IgA nephropathy (IgAN), major cause of kidney failure worldwide, is common in Asians, moderately prevalent in Europeans,
and rare in Africans. It is not known if these differences represent variation in genes, environment, or ascertainment. In a
recent GWAS, we localized five IgAN susceptibility loci on Chr.6p21 (HLA-DQB1/DRB1, PSMB9/TAP1, and DPA1/DPB2 loci),
Chr.1q32 (CFHR3/R1 locus), and Chr.22q12 (HORMAD2 locus). These IgAN loci are associated with risk of other immune-
mediated disorders such as type I diabetes, multiple sclerosis, or inflammatory bowel disease. We tested association of these
loci in eight new independent cohorts of Asian, European, and African-American ancestry (N=4,789), followed by meta-
analysis with risk-score modeling in 12 cohorts (N=10,755) and geospatial analysis in 85 world populations. Four
susceptibility loci robustly replicated and all five loci were genome-wide significant in the combined cohort (P=5610
232–
3610
210), with heterogeneity detected only at the PSMB9/TAP1 locus (I
2=0.60). Conditional analyses identified two new
independent risk alleles within the HLA-DQB1/DRB1 locus, defining multiple risk and protective haplotypes within this
interval. We also detected a significant genetic interaction, whereby the odds ratio for the HORMAD2 protective allele was
reversed in homozygotes for a CFHR3/R1 deletion (P=2.5610
24). A seven–SNP genetic risk score, which explained 4.7% of
overall IgAN risk, increased sharply with Eastward and Northward distance from Africa (r=0.30, P=3610
2128). This model
paralleled the known East–West gradient in disease risk. Moreover, the prediction of a South–North axis was confirmed by
registry data showing that the prevalence of IgAN–attributable kidney failure is increased in Northern Europe, similar to
multiple sclerosis and type I diabetes. Variation at IgAN susceptibility loci correlates with differences in disease prevalence
among world populations. These findings inform genetic, biological, and epidemiological investigations of IgAN and permit
cross-comparison with other complex traits that share genetic risk loci and geographic patterns with IgAN.
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Introduction
IgA nephropathy (IgAN) is a common kidney disease with a
complex genetic determination. This disorder is diagnosed based
on detection of mesangial proliferation and glomerular deposits of
IgA1. Most frequently, IgAN has a progressing course and 20–
50% of cases develop end-stage renal disease (ESRD) within 20
years of follow-up [1]. The disease has been detected among all
ethnicities worldwide, but displays a striking geographic variation.
It is the most common cause of kidney failure in East Asian
countries, has intermediate prevalence in European and US
populations but is rarely reported in populations of African
ancestry. The diagnosis of IgAN requires a kidney biopsy,
complicating accurate determination of heritability and population
prevalence of disease. Autopsy and donor biopsy series suggest a
prevalence of up to 1.3% in Finland [2] and 3.7% in Japan [3].
Familial aggregation of IgAN has also been recognized throughout
the world [4,5,6,7,8,9,10,11] and up to 14% of cases may be
familial [8]. Moreover, family members frequently have aberrant
glycosylation of the hinge region of circulating IgA1, a defect with
an estimated heritability of 40–50% [12,13]. These data suggest a
strong genetic contribution to disease.
Recently, we have completed a large-scale genome-wide
association study (GWAS) involving a cohort of 3,144 sporadic
IgAN cases [14]. The discovery phase samples (1,194 cases and
902 controls) were recruited in Beijing, China and were comprised
of individuals of Han Chinese ancestry. The most associated SNPs
were then followed up in additional cohorts of Han Chinese and
Europeans (1,950 cases and 1,920 controls). In the combined
analysis, we discovered 5 novel susceptibility loci with consistent
effects across individual cohorts. These include 3 distinct intervals
in the MHC-II region on chromosome 6p21, with the strongest
signal encompassing the HLA DQB1/DQA1/DRB1 locus (abbre-
viated as DQB1/DRB1 hereafter). Imputation of classical alleles
suggested that this signal was partially conveyed by a strong
protective effect of the DRB1*1501-DQB1*0602 haplotype. The
second signal on Chr. 6p21 encompassed a ,100 Kb region
containing TAP2, TAP1, PSMB8, and PSMB9 genes (TAP2/
PSMB9 locus) and the third signal on Chr. 6p21 contained the
HLA DPA1/DPB1/DPB2 genes (DPA1/DPB2 locus). Indepen-
dence of these three regions on Chr. 6p21 was demonstrated by
their localization within distinct LD blocks as well as genome-wide
significant associations after rigorous conditional analyses. We also
detected significant association within the Complement factor H (CFH)
gene cluster on Chr. 1q32, where alleles tagging a common
deletion in the CFHR3 and CFHR1 genes imparted a significant
protective effect (CFHR3/R1 locus). Finally, a fifth signal centered
on the HORMAD2 gene on Chr. 22q12 and containing multiple
genes demonstrated significant association with risk of IgAN
(HORMAD2 locus). These five loci individually conferred a
moderate risk of disease (OR 1.25–1.59), but together explained
4–5% of the variation in risk across the populations examined.
To follow-up these studies and better assess the risk imparted by
susceptibility alleles in diverse populations, we performed a
replication study in eight independent case-control cohorts and
performed a meta-analysis of all available genetic data including
the original GWAS, totaling in 10,755 individuals. The expanded
sample size allowed us to formally assess locus heterogeneity,
identify new independent risk variants by conditional analyses and
search for first-order genetic interactions. Finally, we refined a
genetic risk score for IgAN and analyzed differences in the
distributions of the IgAN susceptibility alleles among the major
world populations.
Results
Replication Study
For replication we examined eight cohorts (five European, two
East Asian, and one African-American cohort, totaling 2,228 cases
and 2,561 controls, described in Table S1). While each individual
cohort at best had 40–50% power to replicate original GWAS
findings, the combined replication cohort (2,228 cases and 2,561
controls) provided essentially 100% power for replication across
the range of allele frequencies and odds ratios initially observed
(Table S2).
We genotyped the two top-scoring SNPs for the CFHR3/R1,
TAP2/PSMB9, DPA1/DPB2, and HORMAD2 loci, but four SNPs
were included for the DQB1/DRB1 locus to test for independent
alleles at this interval by conditional analysis. After a standard
assessment of genotype quality control, we performed association
testing within each cohort using the standard Cochrane-Armitage
trend test (Table S3). We also tested for heterogeneity of
associations and performed a meta-analysis under both fixed and
random effects models (Table 1).
Four of the five original GWAS loci displayed significant
replication with direction-consistent ORs and no heterogeneity
comparable to the original findings (Table 1). The strongest
replication was at the DQB1/DRB1 locus and achieved genome-
wide significance in the replication cohort (fixed effects OR 0.75,
P-value 4610
211). The CFHFR3/R1 locus on Chr.1q32, the
HORMAD2 locus on Chr.22q12, and the DPA1/DPB2 locus on
Chr.6p21 were also robustly replicated (fixed effects p-values
3610
23–7610
27), with minimal between-cohort heterogeneity
(I
2,25%). Accordingly, when combined with the four cohorts
studied in the original GWAS, these four loci provided highly
significant evidence of association (fixed effects p-values 3610
210–
5610
232).
In contrast, the TAP2/PSMB9 locus on Chr. 6p21 displayed
direction-consistent replication only in the Italian, German,
Czech, and Japanese cohort but the full replication cohort did
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combined with the four cohorts from the original GWAS, this
locus remained genome-wide significant (fixed effects p-values
1610
28 and 6610
210 for rs9357155 and rs2071543, respectively,
Table 1). As expected, I
2 and Q-tests provided evidence of
heterogeneity and random effects meta-analysis, which explicitly
models heterogeneity, was 1–3 orders of magnitude more
significant than fixed effect meta-analysis at this interval (e.g.
random effects p-value 3610
211,I
2=61% for rs9357155; Table 1).
The heterogeneity was not attributable to differences in ethnicity
or cohort size as the association results varied within Asian and
European cohorts of differing size (Table S3).
Conditional Analysis Reveals New Independent Risk
Alleles within the HLA-DQB1/DRB1 Locus
The top signals in the original GWAS, represented by
rs9275596 and located within the DQB1/DRB1 locus, were
mediated by a very strong protective effect of the DRB1*1501-
DQB1*602 haplotype [14]. However, the SNPs in this interval are
in incomplete LD and conditional analyses in our GWAS [14] and
in an independent study of Europeans [15] had indicated that
additional independent haplotypes also contributed to the signal.
Therefore, taking advantage of our expanded cohort size, we
examined additional SNPs that were in partial LD with rs9275596
to detect potentially independent effects (rs9275224, rs2856717
and rs9275424, which had an r
2 of 0.09 to 0.7 with rs9275596,
Table S4).
After mutually conditioning each SNP on the remaining SNPs,
three of the four SNPs in the DQB1/DRB1 region exhibited a
genome-wide significant independent effect (rs9275596, rs9275224
and rs2856717, conditioned p-vales,5610
28, Table 2). Interest-
ingly, the conditioned effect of the minor allele of rs2856717 was
reversed compared to the crude effect estimate, suggesting that the
adjustment for LD structure has uncovered a risk haplotype in this
region (conditioned OR 1.61, p=2610
210).
The above data indicated that there are multiple risk haplotypes
within the DQB1/DRB1 locus. To better define these findings, we
next phased four-SNP haplotypes at this locus and tested
associations with disease (Table 3). We confirmed a very strong
protective effect of the ATAC haplotype (freq. 0.21) which, based
on our previous imputation analysis, carries the DRB1*1501/
DQB1*602 classical alleles. In addition, we defined a new
protective haplotype (ACAT, freq. 0.13) and a new risk haplotype
(ATAT, freq. 0.05). The ATAC protective haplotype and the
ATAT risk haplotype differ only by the rs9275596-C/T allele,
explaining the reversal of OR for the rs2856717-T allele after
conditioning for rs9275596 (Table 3). Additionally, the GCGT risk
haplotype, tagged by the rs9275424-G allele, exhibited a weaker
protective effect. These results were supported by both Asian and
European cohorts (Table S5). Further support is provided by the
global haplotype association test, which achieved a p-value of
3610
243. Based on these analyses, we concluded that there are at
least three independent haplotypes conferring risk of IgAN within
this region.
Nonetheless, these 3 independent haplotypes in DQB1/DRB1
locus still did not explain associations in other Chr. 6p21 regions
(TAP2/PSMB9 and DPA1/DPB2 loci, respectively represented by
rs9357155 and rs1883414), and a fully adjusted model that
included all independently associated SNPs continued to support
the original GWAS findings of three discrete genome-wide
significant intervals on Chr. 6p21 (Table 4).
First-Order Interaction Screen Reveals Significant
Interaction between CFHR3/R1 and HORMAD2 Loci
We tested the possibility of interaction between the 7 risk-
contributing SNPs and therefore tested for all possible pairwise
interactions (Table S6). We detected strong evidence for a
multiplicative interaction (defined as departure from additivity
on the log-odds scale) between the CFHR3/R1 (rs6677604) and the
HORMAD2 loci (rs2412971). In this interaction, the rs2412971-A
allele has a strong and consistent protective effect among all
genotypic subgroups, but its effects are reversed among homozy-
gotes for the rs6677604-A allele, which closely tags a CFHR3/R1
deletion (Figure 1, Table S6). The significance of this interaction
(p=2.5610
24) exceeds a Bonferroni-corrected threshold for 21
tests, and is most discernable among the European cohorts
(p=1.4610
23), where both SNPs have higher minor allele
frequencies. The 4-df genotypic interaction test was also significant
for these two loci (p=6.4610
23), but the 1-df multiplicative
interaction model provided a better fit.
Improved Prediction of Genetic Risk with a Refined Risk
Score
The original IgAN risk score model was based on the genotypes
of the top scoring SNPs at the 5 independent loci discovered in the
GWAS [14]. We refined this risk score by incorporating the newly
discovered independent effects of rs9275224 and rs2856717 and
the interaction between the CFHR3/R1 and the HORMAD2 loci.
A stepwise regression algorithm in the entire cohort defined a new
risk score that retained the 7 SNPs exhibiting an independent
effect as well as the rs6677604* rs2412971 interaction term
(Table 4). When compared with the original GWAS model, the
newly refined score was more strongly associated with disease risk
and explained a greater proportion of the disease variance in both
the replication and the original GWAS dataset (Table 5).
Moreover, the refined risk score was a highly significant predictor
of disease in each individual replication cohort (Table S7). In all
datasets combined, the new risk score explained 4.7% in disease
Author Summary
IgA nephropathy (IgAN) is the most common cause of
kidney failure in Asia, has lower prevalence in Europe, and
is very infrequent among populations of African ancestry.
A long-standing question in the field is whether these
differences represent variation in genes, environment, or
ascertainment. In a recent genome-wide association study
of 5,966 individuals, we identified five susceptibility loci for
this trait. In this paper, we study the largest IgAN case-
control cohort reported to date, composed of 10,775
individuals of European, Asian, and African-American
ancestry. We confirm that all five loci are significant
contributors to disease risk across this multi-ethnic cohort.
In addition, we identify two novel independent suscepti-
bility alleles within the HLA-DQB1/DRB1 locus and a new
genetic interaction between loci on Chr.1p36 and
Chr.22q22. We develop a seven–SNP genetic risk score
that explains nearly 5% of variation in disease risk. In
geospatial analysis of 85 world populations, the genetic
risk score closely parallels worldwide patterns of disease
prevalence. The genetic risk score also predicts an
unsuspected Northward risk gradient in Europe. This
genetic prediction is verified by examination of registry
data demonstrating, similarly to other immune-mediated
diseases such as multiple sclerosis and type I diabetes, a
previously unrecognized increase in IgAN–attributable
kidney failure in Northern European countries.
Genetic Risk and Prevalence of IgA Nephropathy
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original score. In this model, one standard deviation increase in
the score was associated with nearly 50% increase in the odds of
disease (OR=1.47, 95% CI: 1.42–1.54, P=1.2610
272). This
translates into nearly a 5-fold increase in risk between individuals
from the opposing extremes of the risk score distribution (with tails
defined by $2 standard deviations from the mean).
Geospacial Modeling of Genetic Risk Reveals New
Geographic Patterns in Disease Prevalence
Similar to the GWAS study, we detected pronounced differ-
ences in the distributions of risk alleles among the three different
ethnicities studied: for each of these seven risk loci, the frequency
of the risk alleles was highest in East Asians and lowest in African-
Americans (Figure S1). These differences were also reflected in
highly significant disparities in the risk score distributions by
ethnicity (Figure 2). Motivated by these observations, we examined
global geographic variation in the genetic risk for IgAN by
applying the newly refined IgAN risk score in 6,319 healthy
individuals across 85 worldwide populations. We observed marked
differences in the genetic risk across the world. Overall, the mean
standardized risk score was lowest for Africans, intermediate for
Middle Easterners and Europeans, and highest for East Asians and
Native Americans (Figure 3 and Figure S2). Accordingly, the risk
increased sharply with eastward distance from the prime meridian
(Pearson’s r=0.27, p=3.5610
2108). The same geospatial pattern
were detected if we included only native populations of HGDP
and HapMap-III (Figure S3), demonstrating that the findings are
not biased by inclusion of control populations from the genetic
association study. These data are consistent with the known East-
West gradient in prevalence of IgAN, suggesting that genetic risk
predicts prevalence.
Unexpectedly, higher resolution analysis of the European
continent revealed an additional increase in the risk from South
to North (Pearson’s r=0.11, p=1.3610
29). For example,
northwestern Russians and northern inhabitants of Orkney Islands
(Scotland) have the highest risk scores when compared with the
rest of the European continent (Tables S8 and S9). To confirm
these finding and test whether North-South variation in genetic
risk is also reflected in differences in IgAN occurrence, we
obtained genetic data from additional European populations
(Belgian, British, Finnish, Swedish and Icelandic) and compared
genetic risk scores with the incidence and point prevalence of
IgAN among end-stage renal disease (IgAN-ESRD) populations
across Europe (Table S10). As predicted by the genetic risk score,
our analysis confirmed a strong North-South cline of both
incidence and prevalence across the European continent
(Figure 4). Notably, this analysis includes only patients with end-
stage IgAN, on dialysis or after kidney transplantation, thus it
underestimates the true incidence and population prevalence of
IgAN. Because the point prevalence of IgAN-ESRD (Figure 4b)
can be confounded by differential survival on renal replacement
therapy and differences in kidney biopsy practice by country, we
also examined IgAN-ESRD prevalence expressed as a percentage
of all ESRD (Figure 4c), and ESRD due to biopsy-diagnosed
primary glomerulonephritis (Figure 4d). Regardless of the metric
used to quantify differences in IgAN occurrence, regression of the
genetic risk score and the prevalence data on the average latitude
resulted in positive correlations and parallel trends.
Table 2. Conditional analysis of the HLA-DQB1, HLA-DQA1, HLA-DRB1 locus.
Replication Study
N=4,789 across 8 cohorts
(2,228 cases/2,561 controls)
Replication and GWAS
N=10,755 across 12 cohorts
(5,372 cases/5,383 controls)
UNADJUSTED CONDITIONED UNADJUSTED CONDITIONED
OR P-value OR P-value OR P-value OR P-value CONDITIONING SNPs
rs9275224 0.75 4610
211 0.71 2610
26 0.72 9610
230 0.75 7610
210 rs2856717, rs9275424, rs9275596
rs2856717 0.86 1610
23 1.72 1610
26 0.77 7610
216 1.61 2610
210 rs9275224, rs9275424, rs9275596
rs9275424 1.22 5610
25 1.06 3610
21 1.28 3610
214 1.11 7610
23 rs9275224, rs2856717, rs9275596
rs9275596 0.75 5610
29 0.64 2610
26 0.67 5610
232 0.58 3610
216 rs9275224, rs2856717, rs9275424
doi:10.1371/journal.pgen.1002765.t002
Table 3. Haplotype analysis of rs9275224, rs2856717, rs9275424, and rs9275596 at the HLA-DQB1/DRB1 locus.
All Cohorts: N=10,755 (5,372 cases/5,383 controls)
Freq. Overall Freq. Cases Freq. Controls OR 95%CI P-global
GCAT 0.352 0.365 0.338 -reference- -reference- 3610
243
ATAC 0.213 0.180 0.245 0.69 0.64–0.74
ACAT 0.130 0.119 0.141 0.78 0.71–0.85
ATAT 0.050 0.058 0.043 1.25 1.10–1.42
GCGT 0.246 0.270 0.222 1.12 1.04–1.20
The most common haplotype of 4 major alleles (GCAT) is used as a reference to derive odds ratios for all other haplotypes. Only common haplotypes (frequency .1%)
are tested for association.
doi:10.1371/journal.pgen.1002765.t003
Genetic Risk and Prevalence of IgA Nephropathy
PLoS Genetics | www.plosgenetics.org 5 June 2012 | Volume 8 | Issue 6 | e1002765The co-variation in genetic risk score and IgAN-ESRD
occurrence among world populations may also be in part
influenced by differences in environment, or by other factors such
as local medical guidelines for screening and treatment. To better
distinguish these possibilities, we examined native populations that
live under a uniform environment yet show variation in IgAN risk.
In the densely sampled North Italian populations, the Alpine
villagers of the Valtrompia region have a 3.5-fold higher
prevalence of ESRD attributable to IgAN and primary glomer-
ulonephritis when compared to the national average [16].
Consistent with this prevalence data, the median standardized
risk score in this population was comparable to some of the
Northern European countries and ranked as number one among
the 17 Italian populations sampled in our study (Figure 5, Table
S8).
Conversely, we compared the genetic risk score and IgAN-
ESRD prevalence in populations in the United States, where
diverse ethnicities live under different environments and health
care systems compared to the ancestral populations. The analysis
of the USRDS dataset confirmed the striking ethnic differences in
IgAN-ESRD prevalence (Table S11): the percentage of ESRD
attributable to IgAN was 5-fold greater for Caucasian and 15-fold
greater for Asian Americans compared to African-Americans. This
increased IgAN-ESRD occurrence in Asian- compared to African-
Americans far exceeds the 50% increase in risk predicted by
genetic risk-score (one standard deviation difference), suggesting
the presence of additional unaccounted genetic and environmental
factors (Figure 6).
Discussion
In this study, we examined the largest IgAN case-control
cohorts reported to date. We first verified the five top signals
identified in a recent GWAS for IgAN in independent cohorts and
demonstrated robust replication of four loci, and heterogeneity at
one locus. Using combined dataset of 10,755 individuals, we also
identified novel risk alleles for IgAN in the DQB1/DRB1 locus and
detected a significant interaction between the CFHR3/R1 and the
HORMAD2 loci. We also defined a more powerful genetic risk
score that explained 4.7% in disease variance across all cohorts.
Finally, in examination of 85 world populations, the genetic risk
score paralleled the prevalence of IgAN, confirming the known
East-West cline but also led to the detection of an association of
IgAN-ESRD prevalence with latitude in Europe.
While ten of twelve tested SNPs (four susceptibility loci) were
robustly replicated with direction-consistent ORs across all
cohorts, the TAP2/PSMB9 locus demonstrated moderately high
level of heterogeneity. This locus remained genome-wide
significant in the combined analyses under both fixed and
random effects model. Family-based studies [17,18], sperm
typing experiments [19] and HapMap data have identified a
recombination hotspot directly centered over the TAP2 gene
(22 cM/Mb, 5.5-kb centromeric from the 2 SNPs selected for
replication). We can therefore hypothesize that high heteroge-
neity at this locus is due to the unusually high rates of
recombination in this region, which perturbs LD patterns
between tag-SNPs and causal variants; this situation has been
shown to cause a ‘‘flip-flop’’ phenomenon in association results
[20]. Therefore, higher density of SNP coverage on either side of
the recombination hotspot will be needed to guide future
replication and fine mapping efforts.
In addition to the independent replication of GWAS data, we
identified two new signals in the DQB1/DRB1 region that exhibit
independent genome-wide significant effect in conditional analy-
ses, providing support for multiple causal variants at this locus.
These findings are consistent with previous studies of IgAN
[15,21] and other autoimmune diseases [22,23,24,25], highlight-
ing the complexity of associations in the MHC region. In our
study, the strongest association signal originates in a protective
haplotype tagged by rs9275596-C that carries HLA-DRB1*1501
and DQB1*602, also associated with protection against type I
diabetes [24]. The causal variants underlying the other haplotypes
remain obscure and their discovery will likely require compre-
hensive re-sequencing to define classical alleles.
Genetic interactions have been seldom described in association
studies [26]. We detected a multiplicative interaction between the
CFHR3/R1 and the HORMAD2 loci, which was most evident in
the European cohorts, likely because the frequencies of both
protective variants are considerably higher in this population.
While this interaction was robust to multiple-testing correction for
7 SNPs, it will require confirmation in additional independent
cohorts or via functional studies that examine whether these two
loci are involved in a common biological pathway. Because the
rs6677604-A allele tags a deletion in the CFHR3/CFHR1 genes,
this finding suggests that the absence of these proteins abrogates
the benefit imparted by HORMAD2 protective alleles. It is thus
noteworthy that the HORMAD2 locus encodes several cytokines
(LIF, OSM) that can interact with complement factors [27].
Table 4. The best predictive model for IgAN based on all the genotyped SNPs and their pairwise interaction terms.
Best Predictive Model
Predictor (Reference Allele) Coeficient (b) OR (95%CI) P-value Chr. Annotation of Genes in the Region
rs6677604 (A) 20.49371 0.61 (0.53–0.71) 2.2610
211 1q32 CFH, CFHR1, CFHR3
rs9275224 (A) 20.31307 0.73 (0.67–0.80) 2.5610
211 6p21 HLA-DQB1, -DQA1, -DRB1 (variant 1)
rs2856717 (T) 0.42265 1.53 (1.31–1.78) 8.2610
28 6p21 HLA-DQB1, -DQA1, -DRB1 (variant 2)
rs9275596 (C) 20.51157 0.60 (0.52–0.69) 5.9610
213 6p21 HLA-DQB1, -DQA1, -DRB1 (variant 3)
rs9357155 (A) 20.28621 0.75 (0.69–0.82) 3.8610
210 6p21 HLA-DOB, PSMB8, PSMB9, TAP1, TAP2
rs1883414 (T) 20.1805 0.83 (0.78–0.90) 4.8610
27 6p21 HLA-DPB2, -DPB1, -DPA1
rs2412971 (A) 20.28592 0.75 (0.70–0.81) 2.3610
215 22q12 HORMAD2, MTMR3, LIF, OSM, GATSL3, SF3A1
rs6677604 (A)* rs2412971 (A) 0.23171 1.26 (1.12–1.43) 2.2610
24 – 1q32 by 22q12 interaction term
This model represents the solution of a stepwise logistic regression algorithm (BIC-based stepwise model selection). The coefficients from this model are used to refine
the risk score for IgAN.
doi:10.1371/journal.pgen.1002765.t004
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PLoS Genetics | www.plosgenetics.org 6 June 2012 | Volume 8 | Issue 6 | e1002765Figure 1. Multiplicative interaction between Chr. 22q12 (rs2412971) and Chr. 1q32 (rs6677604) loci. The allelic effects of rs2412971-A
by genotype class of rs9275596 (top signal in the HLA, no interaction) and rs6677604 (top signal in at CFHR1/R3 locus on Chr. 1q32, significant
interaction). The protective effect of rs2412971-A allele is reversed in homozygotes for the rs6677604-A allele, which tags a deletion in CFHR3/R1. The
allelic effects are expressed on the log-odds scale and correspond to beta coefficients of the logistic regression model. Error bars correspond to 95%
confidence intervals.
doi:10.1371/journal.pgen.1002765.g001
Table 5. The comparison of the original and the newly refined IgAN risk score.
Original Risk Score Newly Refined Risk Score
Cohort: N
# R
2* C
** OR
*** P-value
**** R
2* C
** OR
*** P-value
****
Original GWAS Cohorts 5,631 5.0% 0.61 1.51 3.1610
246 5.7% 0.62 1.56 4.1610
252
Replication Cohorts 4,422 2.2% 0.58 1.29 5.4610
217 3.2% 0.59 1.36 3.3610
224
Asian Cohorts Combined 4,582 4.5% 0.60 1.53 3.0610
234 5.0% 0.61 1.52 2.6610
238
European Cohorts Combined 5,386 2.6% 0.58 1.34 3.7610
224 3.6% 0.59 1.42 6.7610
233
All Cohorts Combined 10,053 3.8% 0.60 1.42 6.2610
263 4.7% 0.61 1.47 1.2610
276
The expanded version of this table can be found in supplemental material (Table S7).
#Number of analyzed individuals with 100% non-missing genotypes across all 7 scored loci.
*2: Nagelkerke R square (expressed as percentage).
**C-statistic: area under the ROC curve.
***Odds ratio per one standard deviation of the standardized risk score.
****Wald’s test for risk score as a quantitative predictor of disease status.
doi:10.1371/journal.pgen.1002765.t005
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variance and demonstrated co-variation with IgAN prevalence
across multiple settings. The major limitations of geospatial
modeling include variable sampling density and inadequate
coverage of certain geographic regions. Using the most compre-
hensive resources presently available for geo-genetic analyses, we
found that the genetic risk score strongly paralleled the well-known
East-West gradient in IgAN prevalence [3,28,29,30,31,32]. For
each of these seven risk loci, the frequency of the risk alleles was
highest in East Asians, lowest in African-Americans and interme-
diate in European populations. Accordingly, we detected co-
variation of genetic risk with IgAN-ESRD incidence and
prevalence among Asian-, White- and African-Americans, which
share genetic background but not environment with their ancestral
populations. Representative genetic data for U.S. Native Amer-
icans was not available from HGDP nor HapMap projects,
precluding a direct comparison of their risk score with prevalence.
However, the USRDS data and other reports indicate a high
prevalence of IgAN-ESRD in US Native Americans
[33,34,35,36,37], consistent with their ancestral origin from an
Asian subpopulation that migrated across the Bering land bridge
over 15,000 years ago [38]. In the more homogeneous population
of Northern Italy, the median risk score in the Valtrompia valley
was the highest among Northern Italian populations and
comparable with the Northern European scores, consistent with
Valtrompia’s 3.5-fold higher prevalence of ESRD, which is largely
attributable to IgAN [16]. Taken together, these data strongly
suggested that variation in genetic risk partly explains the variation
in geo-epidemiology of disease.
Because the genetic score captured general trends in IgAN
epidemiology, we also tested whether the Northward gradient in
genetic risk in Europe is mirrored by higher prevalence of kidney
failure from IgAN. The ERA-EDTA data, which are the most
unbiased source of information available, demonstrate that Nordic
countries have over 2-fold higher incidence and prevalence of
IgAN-ESRD compared to the Southern European countries.
Although higher risk of IgAN in Northern Europe has not been
previously appreciated, similar latitudinal risk gradients in
prevalence and incidence have been well established for several
other immune-mediated diseases, including type 1 diabetes
[39,40], multiple sclerosis [41,42], and inflammatory bowel disease
[43]. Interestingly, these disorders share risk alleles with IgAN,
suggesting that variation in common genetic risk factors may
mediate variation in prevalence of autoimmune disorders. Since
our analysis was limited to prevalent IgAN-ESRD in countries
with epidemiological data available and only a portion of IgAN
Figure 2. Differences in the distribution of the 7-SNP genetic risk score by ethnicity. Only healthy control participants of the replication
studies that were fully genotyped at all 7 loci were used in this analysis. Similar to the GWAS study, the risk score distributions were significantly
different by ethnicity (ANOVA p=2.1610
238). The corresponding differences in the distribution of risk alleles are depicted in Figure S1.
doi:10.1371/journal.pgen.1002765.g002
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population prevalence of all IgAN can confirm these findings and
better delineate epidemiological connections to other immune
mediated disorders.
The genetic and environmental factors leading to the observed
geospatial pattern of genetic risk and disease prevalence are not
clear. The pre-modern history of IgAN is not known because this
disease was only first described in 1968 [44], shortly after the
discovery and application of immunofluorescence in the analysis of
kidney tissue. It is well known that mucosal infections can
exacerbate disease, but specific environmental factors influencing
the development of IgAN are not known. Based on a recently
proposed pathogenesis model, the IgAN risk loci participate in
sequential processes leading to the initiation and exacerbation of
IgAN [45]. This may further explain the correlation of the genetic
risk score with disease epidemiology. Interestingly, many of the
IgAN loci are known to exhibit opposing effects on other
autoimmune conditions [14]; for example, the HLA-DQB1 and
HORMAD2 risk alleles are respectively protective for systemic
lupus erythematosus, and inflammatory bowel disease. Thus
balancing selection, in conjunction with local environmental
factors, may be responsible for maintenance of risk alleles in
different populations.
The current IgAN risk score captures a greater proportion of
the disease variance compared to other GWAS for kidney
functions, such as a recent study of 60,000 individual that
reported 13 loci explaining only 1.4% of the variance for estimated
glomerular filtration rate [46]. Nonetheless, the fraction of the
IgAN variation explained remains modest. For example, the one
standard deviation risk-score difference between Asian- and
African-Americans predicts a 50% increase in risk, yet there is
over 10-fold difference IgAN-ESRD occurrence between these
two groups. These data suggest that additional genetic and
environmental factors influence risk. Based on the effect sizes and
allelic frequencies of the discovered SNPs, we estimate that
doubling the GWAS sample size is likely to find up to 7 additional
loci, while tripling the sample size would identify up to 11
additional loci at genome-wide significant p-values,10
28 (calcu-
lation performed as proposed by Park et al. [47]). Conditional
analyses and higher-level interaction screens of more risk loci are
likely to explain additional fraction of the missing heritability and
better explain differences in population prevalence of this disease.
In summary, we report results of the largest collaborative
genetic study of IgAN. We confirm that the IgAN risk loci
discovered in GWAS explain a significant proportion of the
disease risk worldwide and likely contribute to the geographic
variation in disease prevalence. Our geospatial model suggests
previously unrecognized northward risk gradient in Europe, which
will require further confirmation by alternative sources of
prevalence data, such as country specific biopsy-registry data or
kidney donor-biopsy series. The approach presented in this study
may serve as a blueprint for geo-genetic modeling of other
complex traits that exhibit marked geographic differences in
prevalence.
Materials and Methods
Ethics Statement
This investigation was conducted according to the principles
expressed in the Declaration of Helsinki. All subjects provided
informed consent to participate in genetic studies and the
Institutional Review Board of Columbia University as well as
local ethic review committees for each of the individual cohorts
approved our study protocol.
Figure 3. Worldwide geospatial risk analysis. Surface interpolation of the standardized risk score over Africa and Euroasia (main), and Americas
(inset). Symbols represent the locations of sampled populations: HGDP (circles), HapMap-III (diamonds), and healthy controls from this study
(triangles).
doi:10.1371/journal.pgen.1002765.g003
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The case-control cohorts analyzed in this study were contrib-
uted by clinical nephrology centers across Europe, Asia, and North
America (Table S1). All cases carried a biopsy diagnosis of IgAN
defined by typical light microscopy features and predominant IgA
staining on kidney tissue immunofluorescence, in the absence of
liver disease or other autoimmune conditions. Each individual
cohort of cases was accompanied by a control cohort of similar
size, matched based on self-reported ethnicity and recruited from
the same clinical center. The French cohort was composed of two
sub-cohorts: the St. Etienne cohort recruited in the University
North Hospital of Saint Etienne (289 cases and 244 controls), and
the GN-Progress cohort recruited from the nephrology depart-
ments of the Paris region (207 cases and 159 controls). The Italian
Figure 4. Correlation of average country latitude with country-specific genetic risk and IgAN–attributable ESRD across the
European continent. The South to North latitude is indicated on the X-axis. The median genetic risk (x) is indicated on the right Y-axis. The
following incidence and prevalence metrics (o) are indicated on the left Y-axis: (panel a) the incidence of ESRD due to IgAN per million population
(correlation with latitude: r=0.54, p=0.05); (panel b) the prevalence of ESRD due to IgAN per million population (correlation with latitude: r=0.47,
p=0.10); (panel c) the percent of IgAN patients among all ESRD cases (correlation with latitude: r=0.67, p=0.01); and (panel d) among ESRD cases
due to primary glomerular disease (correlation with latitude: r=0.71, p=0.006). All p-values are derived based on a two-sided hypothesis test.
doi:10.1371/journal.pgen.1002765.g004
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cohort recruited in the clinical centers of Genova, Torino, Brescia,
Trento, Modena, Bologna, and Trieste (410 cases and 524
controls), and the South Italian cohort recruited in Foggia (81
cases and 80 controls). The German cohorts also represent two
recruitment sites: the Stop-IgAN cohort recruited among the
participants of the Stop-IgAN clinical trial based in Aachen (150
cases and 293 controls), and the Hamburg-Eppendorf cohort from
northern Germany (101 cases and 80 controls). The Czech and the
Hungarian cohorts were recruited through the Department of
Nephrology, 1st Faculty of Medicine and General University
Hospital, Charles University in Prague (245 cases and 223
controls) and the Nephrology Department of the University of
Pe ´cs (139 cases and 305 controls), respectively. The Japanese
participants (264 cases and 294 controls) were recruited by the
nephrologists of Niigata University. The Beijing cohort (333 cases
and 289 controls) was recruited by the Renal Division of the
Peking University First Hospital. Finally, our African-American
cohort (34 cases and 60 controls) was recruited at Columbia
University (New York, NY) and at the University of Alabama
(Birmingham, AL). This smaller cohort is unique, as IgAN is
exceedingly rare among individuals of African ancestry. In total,
2,253 cases and 2,621 controls were available for genotyping in the
replication study. The composition and recruitment of the GWAS
cohorts have been discussed in detail elsewhere [14].
Genotyping and Genotype Quality Control
The genotyping was performed by KBiosciences (Hoddeston,
England). and genotype calls were determined using an automated
clustering algorithm the (SNP Viewer v.1.99, KBiosciences, 2008).
The genotype clusters were also examined visually across all plates,
to assure lack of technical artifacts. The overall genotyping rate
across all samples was 98.2%. For quality control we calculated
minor allele frequencies, as well as per-SNP and per-individual
rates of missingness within each case-control cohort separately.
Additionally, we tested for Hardy-Weinberg equilibrium among
the control groups from each cohort to assure lack of bias due to
genotyping artifacts or population stratification. All SNPs included
in the final analyses had minor allele frequency greater than 1%,
per-SNP missingness rate less than 5%, and all passed the HWE
test in controls (p.1610
22). Individuals with more than 2 missing
genotypes out of the 12 loci were also excluded from the analysis.
The participants of the smaller GN-Progress study (207 cases
and 159 controls) were genotyped using the Illumina Hu-
manCNV370-duo chip at the Centre National de Ge ´notypage
(CEA, Evry, France). The analysis of intensity clusters and
genotype calls were performed using the Illumina Genome Studio
software. Of 366 genotyped individuals, two cases and 1.8% of
SNPs were excluded based on low call rates (,95%). The overall
genotyping rate was 99.6%. In total, 6 of 12 SNPs analyzed for
replication were also present on the Illumina HumanCNV370-duo
chip. The genotypes at the reminder loci were imputed using the
phased HapMap-III CEU reference dataset (see Web Resources).
The imputation was performed simultaneously for cases and
controls, using MACH 1.0 software (see Web Resources). We used
a standard single-step imputation approach, with 60 rounds of
Markov Chain iterations to estimate the crossover maps, error rate
maps, and all missing genotypes across each analyzed locus. The
Figure 5. High-resolution geospatial risk analysis for Italy. A well defined region of higher genetic risk was uncovered in Northern Italy that
centers on Valtrompia, Brescia, and Cremona (median standardized risk scores 0.31, 0.24 and 0.24, respectively). The healthy individuals from
Valtrompia had the highest risk scores when compared to 16 other Italian populations sampled.
doi:10.1371/journal.pgen.1002765.g005
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average estimated correlation between imputed genotypes and
experimental genotypes of 0.98 (range 0.94–1.0). Consequently,
association analyses using either the allelic dosage approach that
accounts for imputation uncertainty, or the most likely genotype
approach yielded similar results. Therefore, the most probable
genotype calls were used in the downstream analyses. In the final
quality control step, we compared the allelic frequencies and effect
estimates between the two French cohorts (GN-Progress and St.
Etienne). For each locus, we observed nearly identical frequencies
among cases and controls and the odds ratios were homogenous
between the two cohorts. The formal heterogeneity tests were not
statistically significant for any of the tested loci (Cochrane’s Q-test
P.0.05, average I
2=0). Therefore, these two cohorts were
combined into a single cohort of 493 cases and 402 controls.
Similarly to the French cohorts, there was no significant
heterogeneity at any of the loci for the two smaller German
cohorts (STOP-IgAN and Hamburg-Eppendorf), and these were
also combined into a single cohort of 249 cases and 372 controls.
Analysis of the Northern and Southern Italian cohorts suggested
some heterogeneity at 3 out of 12 SNPs (I
2=40–50%). Although
these observations were not statistically significant (Q-test
P.0.05), we used a conservative stratified approach for all
downstream analyses for these two cohorts. The final summary of
all study cohorts before and after quality control is provided in
Table S1.
Power Calculation
We performed a power calculation for the final replication
cohort size of 4,789 individuals (2,228 cases/2,561 controls) as a
function of disease allele frequency and genotype relative risk
(Table S2). The power was calculated in reference to a protective
allele, with the range of allelic frequencies and effects comparable
to the ones observed in the original GWAS. Assumptions included
disease prevalence of 1%, log-additive model, no heterogeneity,
and alpha=0.01 (Bonferroni-adjusted considering five indepen-
dent loci tested). This analysis confirmed that our study had ample
power (nearly 100% for most loci) to replicate the associations
observed in the initial GWAS. The power calculations were
performed using QUANTO v.1.2 software [48].
Figure 6. Genetic risk and IgAN–attributable ESRD among major US ethnicities. The relationship between IgAN risk scores (red line) and
IgAN incidence and prevalence (bars) among US ethnicities are shown. The following metrics of IgAN occurrence are depicted: (panel a) the incidence
of ESRD due to IgAN per million population by ethnicity, (panel b) the prevalence of ESRD due to IgAN per million population by ethnicity, (panel c)
percent of IgAN among the total ESRD population by ethnicity; and (panel d) percent of IgAN among ESRD due to glomerular disease by ethnicity.
doi:10.1371/journal.pgen.1002765.g006
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The primary association analyses were performed using PLINK
version 1.07 [49]. Similar to GWAS, we selected a standard 1-df
Cochran-Armitage trend test as the primary association test. We
also estimated the per-allele odds ratios and 95% confidence
intervals for all tested SNPs within each individual cohort. The
results across multiple cohorts were combined using an inverse
variance-weighted method under a fixed-effects model (PLINK),
as well as using a random effects model as proposed by Han and
Eskin (METASOFT) [50]. We also tested for heterogeneity across
cohorts by performing a formal Cochrane’s Q heterogeneity test as
well as by estimating the heterogeneity index (I
2) [51].
Conditional Analyses
The conditional association tests of the HLA loci were
performed after controlling for the genotypes of the conditioning
SNPs within each cohort using logistic regression (PLINK). The
adjusted (conditioned) effect estimates were then combined across
cohorts using a fixed effect meta-analysis considering no significant
heterogeneity across these loci. For the purpose of validation of
this approach, we also combined the results by adding cohort
information as an additional covariate in the stratified analysis
within the logistic regression framework. As expected, the results of
both approaches were similar.
Haplotype-Based Association Tests
These analyses were carried out in PLINK v1.07 [49].
Haplotypes were first phased using EM algorithm across the
HLA-DQB1, HLA-DQA1, HLA-DRB1 region. The haplotype
frequencies were estimated in the cases and controls separately,
as well as jointly in the entire cohort. Only common haplotypes
with overall frequency .1% were included in the association tests.
Global haplotype association test was performed using a x
2 test
with n-1 degrees of freedom for n common haplotype groups. The
ORs and the corresponding 95% confidence intervals were
estimated in reference to the most common haplotype (GCAT,
frequency ,35%).
First-Order Interaction Analyses
To explore the possibility of interactions between the 7
independent risk variants, we screened all possible pairwise
interaction terms for association with disease within the framework
of logistic regression models (R version 2.10). As a screening test,
we used 1-df LRT to compare two nested models: one with main
effects only and one with main effects and a multiplicative (logit-
additive) interaction term. We included cohort membership as a
fixed covariate in both of these models. For this analysis we
selected a Bonferroni-adjusted significance of 2.4610
23,a
conservative threshold that accounts for all 21 pairwise interaction
terms tested. Significant interactions from this analysis were also
tested using a 4-df genotypic interaction test. In this test, we
compared a model with allelic effects, dominant effects, and their
interaction terms with a reduced model with no interaction terms.
We followed the coding proposed by Cordell and Clayton: for
each SNP i we modeled its allelic effect xia by coding the genotypes
AA, AB, and BB as xia=21, 0, 1; we modeled dominance effects
as xid=20.5, 0.5, 20.5 for the genotypes AA, AB, and BB,
respectively [52].
Distributions of Protective Alleles and Risk Score Analyses
Each study participant was scored for the number of risk alleles
and the distributions of protective alleles were compared between
cohorts of different ethnicity. Only individuals with complete
genotype information at the 7 scored loci (14 alleles) were included
in this analysis. The distributions were analyzed separately for
cases and controls. A x
2 goodness-of-fit test was used to derive p-
values for comparison of distributions. Because of a relatively small
number of individuals at the tails of the distributions, for the
purpose of statistical testing the tails of the distributions were
binned into single-bin categories to achieve expected cell counts
.5.
To confirm the results of conditional analyses and refine the
genetic risk score proposed in the original GWAS, we subjected
the genotype data from the entire cohort to a stepwise regression
algorithm that selects significant covariates for the best predictive
regression model based on Bayesian Information Criterion (the step
function, R version 2.10). At model entry, we included all 12
genotyped SNPs, all 21 tested interactions, as well as cohort
membership as a fixed covariate. Consistent with the results of our
conditional analysis, the stepwise algorithm retained only the 7
SNPs exhibiting an independent effect along with the
rs6677604*rs2412971 interaction term. All other terms were
automatically dropped from the regression model.
The risk score was calculated as a weighted sum of the number
of protective alleles at each locus multiplied by the log of the OR
for each of the individual loci from the final fully adjusted model.
Only individuals with non-missing genotypes for all 14 alleles were
included in this analysis. The risk score was standardized across all
populations using a z-score transformation, thus the standardized
score represented the distance between the raw score and the
population mean in units of standard deviation. The percentage of
the total variance in disease state explained by the risk score was
estimated by Nagelkerke’s pseudo R
2 from the logistic regression
model with the risk score as a quantitative predictor and disease
state as an outcome. The C-statistic was estimated as an area
under the receiver operating characteristic curve provided by the
above logistic model. These analyses were carried out with SPSS
Statistics version 19.0.
Geospatial Analyses
For this purpose, we used publicly available genotype data of
the Human Genome Diversity Panel (HGDP; 1,050 individuals
representative of 52 worldwide populations), HapMap III (1,184
individuals representative of 11 populations), along with healthy
controls genotyped as part of this study (4,547 individuals
representative of 25 recruitment sites). The HGDP individuals
have been previously genotyped for 660,918 markers using
Illumina 650Y arrays (Stanford University). First, SNPs with
genotyping rate,95% and samples with an overall call
rate,98.5% were removed from the genome-wide data. Only
1,042 individuals with all 14 non-missing alleles at the 7 analyzed
risk score loci were included in the final analysis. The geographic
coordinates for the HGDP populations were downloaded from the
CEPH website (see Web Resources). The HapMap III genotype
data have been generated using two platforms: the Illumina
Human1M (Wellcome Trust Sanger Institute) and the Affymetrix
SNP 6.0 (Broad Institute). These files were merged into a single
dataset of 1,440,616 markers, from which we removed (1) SNPs
with genotyping rate,95%, (2) samples with an overall call
rate,98.5%, (3) all non-founders from mother-father-child trios,
and (4) individuals with missing genotypes at any of the 7 SNP loci
used for risk scoring. In the global geospatial analyses, we excluded
US-recruited individuals of African American (ASW), European
(CEU), and Asian (CHD) ancestry considering non-specific
geographic origin of these populations. However, the population
of Guajarti Indians recruited in Houston (GIH) was mapped to the
northwestern part of the Indian subcontinent, as these individuals
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speak the Gujarati language, and trace their ancestry to the region
of Gujarat. In total, 730 HapMap III individuals representative of
8 populations met our selection criteria and were included in the
final analysis.
Because many European populations are underrepresented in
HGDP and HapMap III datasets, we also included a total of 4,462
healthy controls from the GWAS and replication studies that were
collected across 25 recruitment centers participating in our studies.
Similar to the above criteria, only individuals with non-missing
genotypes at all 7 scored SNPs were included in this analysis. The
geographic coordinates for our populations were based on the
location of recruitment centers and determined with Google Earth
(see Web Resources). This resulted in a final dataset of 6,319
individuals sampled across 85 worldwide populations for geospa-
tial analysis.
We fitted a 3
rd degree polynomial trend surface based on the
latitude, longitude, and median standardized risk score for each of
the 85 populations using least squares approach (Spatial package
version 7.3-2, R version 2.10). For higher resolution maps, we used
kriging technique and accounted for the possibility of spatial
correlation of errors among more densely sampled populations by
modeling the covariance function in an exponential form. The
estimated risk surfaces were projected over the major continents
using Maps package version 2.1–6 (R version 2.10).
Analysis of Prevalence and Incidence Data
We obtained case counts of prevalent and incident ESRD
stratified by primary renal diagnosis and by ethnicity from the
United States Renal Data Systems (2011 USRDS Data Atlas, see
Web Resources). For Europe, we obtained prevalent and incident
ESRD case counts from the European Renal Association and
European Dialysis and Transplant Association (ERA-EDTA
Renal Registry, see Web Resources). Comprehensive data were
available for a total of 13 European countries participating in this
registry. We calculated the prevalence of ESRD due to IgAN using
three definitions: (1) proportion of all ESRD cases attributable to
IgAN, (2) proportion of all ESRD cases from primary glomeru-
lonephritis attributable to IgAN, and (3) total number of ESRD
cases due to IgAN per million population (PMP). The prevalence
data for both USRDS and ERA-EDTA datasets were calculated
for the same timepoint of December 31
st, 2009. The incidence of
ESRD due to IgAN was estimated using all the available data over
a 3-year period for the ERA-EDTA registry (2007–2009), and a 5-
year period for the USRDS registry (2005–2009). For correlation
of genetic risk score with disease prevalence in the US, we scored
representative samples of the three major US ethnic groups: 303
US Caucasians (CEU founders from HapMap-3 and healthy US
controls from our original GWAS), 103 African-Americans (ASW
founders from HapMap-3 and healthy controls from this study),
and 74 Asian-Americans (CHD founders from HapMap-3). For
correlation of genetic risk with disease prevalence in Europe, we
calculated median standardized risk scores at a country level for 13
European countries for which we obtained genotype data. We
confirmed the South-North disease gradient by regressing the
prevalence and risk score data against each country’s average
latitude. The correlation and regression analyses were conducted
in SPSS Statistics version 19.0.
Web Resources
HAPMAP PHASE III Data: http://hapmap.ncbi.nlm.nih.gov/
downloads/phasing/2009-02_phaseIII
HGDP Genotype Data: http://hagsc.org/hgdp
HGDP Population Data: http://www.cephb.fr/en/hgdp
MACH: http://www.sph.umich.edu/csg/abecasis/MaCH
PLINK: http://pngu.mgh.harvard.edu/,purcell/plink
METASOFT: http://genetics.cs.ucla.edu/meta
CRAN: http://cran.r-project.org
GOOGLE EARTH: http://www.google.com/earth
SPATIAL: http://cran.r-project.org/web/packages/spatial
MAPS: http://cran.r-project.org/web/packages/maps
USRDS Data Atlas 2011: http://www.usrds.org/atlas.aspx
ERA-EDTA Registry Annual Report 2009: http://www.era-
edta-reg.org
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Figure S1 Differences in the distributions of risk alleles at the 7
susceptibility loci among major ethnicities in the replication cohorts.
Similar to the GWAS study, the distribution of the risk alleles
differed by ethnicity: Asian controls carry more risk alleles compared
to healthy Europeans or African-Americans (p=3610
255 and
p=5 610
27, respectively); European controls have more risk alleles
compared to African-Americans (p=6610
23).
(PDF)
Figure S2 Inter-continental differences in the genetic risk score
based on 85 worldwide populations used for geospatial analysis.
(PDF)
Figure S3 Geospatial risk model for native populations. Surface
interpolation of the standardized risk score for HGDP (circles) and
HapMap-III (diamonds) datasets. The risk increases globally with
the distance from the prime meridian (Pearson’s r=0.31,
p,2.2610
216) and northward within Europe (Pearson’s r=0.13,
p=6.6610
24).
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Table S1 Summary of the case-control replication cohorts
before and after quality control measures.
(PDF)
Table S2 Power calculation. Study power for the replication
cohort of 4,789 individuals (2,228 cases/2,561 controls) as a
function of disease allele frequency and genotype relative risk. The
power was calculated in reference to a protective allele; the range
of allelic frequencies and effects was based on the results of the
original GWAS. Assumptions include: disease prevalence of 1%,
log-additive model, no heterogeneity, and alpha=0.01 (Bonfer-
roni-adjusted considering five independent loci tested).
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Table S3 Case-control association results for the individual
replication cohorts.
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Table S4 Pairwise LD between the SNPs of the HLA region: r2
(top right half) and D9 (bottom left half) for all cohorts (top),
Europeans (middle) and Asians (bottom).
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Table S5 Haplotype analysis of rs9275224, rs2856717,
rs9275424, and rs9275596 at the HLA- DQB1/DRB1 locus. The
most common haplotype of 4 major alleles (GCAT) is used as a
reference to derive odds ratios for all other haplotypes. Only
common haplotypes (frequency.1%) are tested for association.
(PDF)
Table S6 All possible 1
st order multiplicative interactions
between the 7 SNPs with independent effects on disease risk.
Statistical significance is assessed using a Bonferroni-corrected
threshold, alpha 0.05/21=2.4610
23.
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Table S9 Asian, Oceanian, and American populations included
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